Company intelligence / Profile preview

OSPT

Ownership: Private
Development stage: Other

Overview

Lead program enrolled Phase IIb trial in recurrent osteosarcoma with results expected Q4 2024. Received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status. Platform shows promise across several solid tumor types expressing HER2.

Therapeutic areas: Oncology
Modalities: ImmunotherapyAntibody-drug conjugateLive biotherapeutic product therapy (bioengineered Listeria monocytogenes)
Industry: Biotech

Partnerships

Johnson & Johnson Innovation – JLABS

Beyond the preview

Go deeper on OSPT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OSPT.

Explore the full profile